KraneShares Hang Seng TECH Index ETF vs uniQure N.V. Ordinary Shares — how do they compare? KraneShares Hang Seng TECH Index ETF trades at $11.52 (market cap $46.22M), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: uniQure N.V. Ordinary Shares is far larger — about 32× KraneShares Hang Seng TECH Index ETF's market cap, and uniQure N.V. Ordinary Shares is trading nearer its 52-week high, KraneShares Hang Seng TECH Index ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold KraneShares Hang Seng TECH Index ETF for 44 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| KTEC | QURE | |
|---|---|---|
Market Cap | $46.22M | $1.48B |
Volume | 22,698 | 2,488,780 |
Sector | Sector/Thematic | Health |
52-Week High | $18.36 | $70.59 |
52-Week Low | $11.41 | $9.03 |
Typical Hold Time | 44 Days | 0 Days |
Enterprise Value | — | $728.62M |
Signals from Pluang's Aura AI — not financial advice
KTEC trades at $11.61 with no recent price movement. The stock shows bearish technical signals with 15 sell indicators versus 2 buy signals. Fundamentally, the company reported $120.04M revenue in 2016 with a net loss of $697K, though cash flow improved to positive $2.77M. Recent news highlights China's AI competition potentially benefiting tech ETFs like KTEC.
KTEC faces mixed prospects with improving cash flow but inconsistent profitability. The bearish technical outlook and volatile earnings history suggest caution, though exposure to AI sector growth through ETF positioning offers potential upside. Key risks include competitive pressures and execution challenges in maintaining positive momentum.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
KTEC tracks the Hang Seng TECH Index, providing targeted exposure to the 30 largest technology companies listed on the Hong Kong Stock Exchange. It focuses on innovative, internet-based businesses across sectors like e-commerce, fintech, cloud computing, and digital technology.
Read more on KTEC →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →